Shots:

• The approval is based on a P-III study that evaluates Invega hafyera (q6mos.- twice-yearly injectable) vs Invega trinza in 702 adults in a ratio (2:1) aged 18-70yrs. with schizophrenia from 20 countries
• The results showed non-inferiority on 1EPs of time to 1st relapse @12mos. in ITT & per-protocol analysis sets.- patients were relapse-free (92.5% vs 95%) @12mos. & safety profile was consistent with previous studies with no new safety signals were observed
• Additionally- patients who take Invega Hayfera must first be treated with Invega Sustenna for 4mos. or Invega Trinza for 1mos. injection cycle. Janssen’s CarePath provides a comprehensive support program to help patients on Invega hafyera

Ref: PR Newswire | Image: Janssen